FDA to bring in piloted quality inspection procedures for devices in the autumn
This article was originally published in Clinica
The FDA plans to introduce its re-engineering proposal for device inspections this autumn in the US following the resounding success of a three-month pilot of the programme.
You may also be interested in...
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Among the largest gaps in safety data is non-clinical research on CBD use's effect on developing fetus and adolescent brain, in utero/lactational exposure, reproductive toxicity and the potential for a latency period before toxicity, says FDA neuroscientist Andrew Shen.
The templates from the US agency provide guidance to manufacturers developing antibody tests for clinical or at-home use.